Analytical Quality by Design Approach to Test Method Development and Validation in Drug Substance Manufacturing
Pharmaceutical industry has been emerging rapidly for the last decade by focusing on product Quality, Safety, and Efficacy. Pharmaceutical firms increased the number of product development by using scientific tools such as QbD (Quality by Design) and PAT (Process Analytical Technology). ICH guidelin...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-01-01
|
| Series: | Journal of Chemistry |
| Online Access: | http://dx.doi.org/10.1155/2015/435129 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832554195394232320 |
|---|---|
| author | N. V. V. S. S. Raman Useni Reddy Mallu Hanimi Reddy Bapatu |
| author_facet | N. V. V. S. S. Raman Useni Reddy Mallu Hanimi Reddy Bapatu |
| author_sort | N. V. V. S. S. Raman |
| collection | DOAJ |
| description | Pharmaceutical industry has been emerging rapidly for the last decade by focusing on product Quality, Safety, and Efficacy. Pharmaceutical firms increased the number of product development by using scientific tools such as QbD (Quality by Design) and PAT (Process Analytical Technology). ICH guidelines Q8 to Q11 have discussed QbD implementation in API synthetic process and formulation development. ICH Q11 guidelines clearly discussed QbD approach for API synthesis with examples. Generic companies are implementing QbD approach in formulation development and even it is mandatory for USFDA perspective. As of now there is no specific requirements for AQbD (Analytical Quality by Design) and PAT in analytical development from all regulatory agencies. In this review, authors have discussed the implementation of QbD and AQbD simultaneously for API synthetic process and analytical methods development. AQbD key tools are identification of ATP (Analytical Target Profile), CQA (Critical Quality Attributes) with risk assessment, Method Optimization and Development with DoE, MODR (method operable design region), Control Strategy, AQbD Method Validation, and Continuous Method Monitoring (CMM). Simultaneous implementation of QbD activities in synthetic and analytical development will provide the highest quality product by minimizing the risks and even it is very good input for PAT approach. |
| format | Article |
| id | doaj-art-fde64835856143e68e79463dbd0372ce |
| institution | Kabale University |
| issn | 2090-9063 2090-9071 |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Chemistry |
| spelling | doaj-art-fde64835856143e68e79463dbd0372ce2025-02-03T05:52:17ZengWileyJournal of Chemistry2090-90632090-90712015-01-01201510.1155/2015/435129435129Analytical Quality by Design Approach to Test Method Development and Validation in Drug Substance ManufacturingN. V. V. S. S. Raman0Useni Reddy Mallu1Hanimi Reddy Bapatu2Hetero Drugs Ltd. (R&D), Plot No. B. 80 & 81, APIE, Balanagar, Hyderabad, Andhra Pradesh, IndiaDepartment of Chemistry, Sri Krishnadevaraya University, Anantapur, Andhra Pradesh, IndiaDepartment of Chemistry, JNT University, Hyderabad, Andhra Pradesh, IndiaPharmaceutical industry has been emerging rapidly for the last decade by focusing on product Quality, Safety, and Efficacy. Pharmaceutical firms increased the number of product development by using scientific tools such as QbD (Quality by Design) and PAT (Process Analytical Technology). ICH guidelines Q8 to Q11 have discussed QbD implementation in API synthetic process and formulation development. ICH Q11 guidelines clearly discussed QbD approach for API synthesis with examples. Generic companies are implementing QbD approach in formulation development and even it is mandatory for USFDA perspective. As of now there is no specific requirements for AQbD (Analytical Quality by Design) and PAT in analytical development from all regulatory agencies. In this review, authors have discussed the implementation of QbD and AQbD simultaneously for API synthetic process and analytical methods development. AQbD key tools are identification of ATP (Analytical Target Profile), CQA (Critical Quality Attributes) with risk assessment, Method Optimization and Development with DoE, MODR (method operable design region), Control Strategy, AQbD Method Validation, and Continuous Method Monitoring (CMM). Simultaneous implementation of QbD activities in synthetic and analytical development will provide the highest quality product by minimizing the risks and even it is very good input for PAT approach.http://dx.doi.org/10.1155/2015/435129 |
| spellingShingle | N. V. V. S. S. Raman Useni Reddy Mallu Hanimi Reddy Bapatu Analytical Quality by Design Approach to Test Method Development and Validation in Drug Substance Manufacturing Journal of Chemistry |
| title | Analytical Quality by Design Approach to Test Method Development and Validation in Drug Substance Manufacturing |
| title_full | Analytical Quality by Design Approach to Test Method Development and Validation in Drug Substance Manufacturing |
| title_fullStr | Analytical Quality by Design Approach to Test Method Development and Validation in Drug Substance Manufacturing |
| title_full_unstemmed | Analytical Quality by Design Approach to Test Method Development and Validation in Drug Substance Manufacturing |
| title_short | Analytical Quality by Design Approach to Test Method Development and Validation in Drug Substance Manufacturing |
| title_sort | analytical quality by design approach to test method development and validation in drug substance manufacturing |
| url | http://dx.doi.org/10.1155/2015/435129 |
| work_keys_str_mv | AT nvvssraman analyticalqualitybydesignapproachtotestmethoddevelopmentandvalidationindrugsubstancemanufacturing AT usenireddymallu analyticalqualitybydesignapproachtotestmethoddevelopmentandvalidationindrugsubstancemanufacturing AT hanimireddybapatu analyticalqualitybydesignapproachtotestmethoddevelopmentandvalidationindrugsubstancemanufacturing |